Previous 10 | Next 10 |
2024-04-25 18:33:59 ET Summary CytomX Therapeutics is a biotech company developing anticancer therapeutics using a technology that activates an immune response within the tumor microenvironment. Their main pipeline candidate, CX-904, is a bispecific "probody" targeting EGFR and CD...
2024-04-22 10:06:27 ET CytomX Therapeutics ( NASDAQ: CTMX ) has been upgraded to Neutral from Underweight by J.P Morgan Research as it believes the company is entering a catalyst rich period over the next 6–18 months.... Read the full article on Seeking Alpha For ...
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study ( NCT06265688 ) of CX-2051 in pa...
- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date - - CytomX-retains US co-commercialization and economic rights for select programs - SOUTH SAN FRANCISCO, Calif., ...
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the developme...
- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration projects in broad CytomX-Astellas alliance on T-cell engaging bispecifics - - Cyto...
2024-03-12 13:26:43 ET More on CytomX CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on CytomX Historical earnings data for CytomX Financial information for CytomX Read the full article on Seeki...
2024-03-12 08:28:49 ET More on Pre-market losers & stocks. Renalytix approached by potential buyer, stock rallies 28% Renalytix surges after Medicare draft decision on lead product Seeking Alpha’s Quant Rating on ASLAN Pharmaceuticals Historical ea...
2024-03-11 18:39:06 ET CytomX Therapeutics, Inc. (CTMX) Q4 2023 Results Conference Call March 11, 2024 05:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Conference C...
2024-03-11 16:46:57 ET Gainers: ESGEN Acquisition ( ESAC ) +40% . LifeMD ( LFMD ) +7% . Mission Produce ( AVO ) +4% . Flex ( FLEX ) +4% . Purple Innovation ( PRPL ) +3% . Losers: Power & Digital Infrastruc...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...